Why the study?
Does simulated dabigatran treatment according to the European label reduce stroke, systemic embolism, and bleeding compared to well-controlled warfarin in patients with atrial fibrillation?
Does simulated dabigatran treatment according to the European label reduce stroke, systemic embolism, and bleeding compared to well-controlled warfarin in patients with atrial fibrillation?
Simulated adherence to the European label for dabigatran in atrial fibrillation patients demonstrates superior efficacy and safety compared to well-controlled warfarin.
No takes yet. Share an insight, caveat, or question.
May support EU-label dabigatran in AF; leaves open need for randomized confirmation before practice change.
Clemens et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: